Article
Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer.
The bone & joint journal - 1 Apr 2017
Willeumier J J, van der Hoeven N M A, Bollen L, Willems L N A, Fiocco M, van der Linden Y M, Dijkstra P D S
Abstract excerpt
AIMS: This study aims to assess first, whether mutations in the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma (kRAS) genes are associated with overall survival (OS) in patients who present with symptomatic bone metastases from non-small cell lung cancer (NSCLC) and secondly, whether mutation status should be incorporated into prognostic models that are used when deciding on the appropriate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.